Trump hits long-term pledge as US prices of weight loss drugs slashed
President Donald Trump achieved one of his key targets in the healthcare sector, following agreements with Eli Lilly and Novo …
Post
-
-
Abzena and Mabqi partner for drug development solution
Abzena and Mabqi have announced a partnership integrating antibody discovery capabilities with development and manufacturing services for a drug development …
-
Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz
Alvotech and Advanz Pharma have announced the receipt of marketing authorisations from the UK Medicines and Healthcare products Regulatory Agency …
-
J&J’s Caplyta wins MDD approval to extend revenue horizon
Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J&J) saw in …
-
Former blockbuster Linzess grows label with paediatric IBS-C approval
The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with irritable bowel …
-
Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity
Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by the …
-
Cencora to invest $1bn in US pharma distribution network
Cencora is set to invest $1bn by 2030 for expanding its US pharmaceutical distribution network, adding resilience and capacity to …
-
Leukogene Therapeutics gains FDA ODD status for M2T-CD33
Leukogene Therapeutics has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for M2T-CD33 (LTI-214), …
-
Novo Nordisk latest outlook trim shows “quick momentum loss”
Novo Nordisk has cut its outlook for 2025 as lower expectations for glucagon-like peptide-1 receptor agonists (GLP-1RA) continue to hit …
-
Agentic, deeply embedded AI constitutes the “next wave” of tech
Artificial intelligence (AI) has become a key buzzword in the pharmaceutical industry, with most, if not all, companies looking to …
-
Avant and SGAustria form JV to develop diabetes therapy
Avant Technologies and SGAustria have announced a joint venture (JV) and licence agreement to advance a therapy for diabetes using …
-
The latest regulatory updates affecting parenteral packaging
Regulations are the cornerstone of the pharmaceutical industry, with parenteral packaging often an area of scrutiny due to its importance …
-
Innovation meets convenience: Redefining lyophilized drug delivery for patients
Over the past few decades, the pharmaceutical industry has seen a steady shift toward parenteral self-administration and home-based care. As …
-
Sri Lanka’s drug pricing reform: balancing affordability with sustainability
Ensuring fair and transparent pharmaceutical pricing was a key promise of Sri Lanka’s ruling government’s election manifesto, and that promise …
-
Novo Nordisk and Pfizer’s bidding war for Metsera escalates despite legal threats
Novo Nordisk has raised its offer to buy out obesity biotech Metsera to $10bn as a bidding war with Pfizer …
